FARN vs. ERGO, SLN, PRTC, OXB, HZD, VRP, ARIX, BVXP, AVCT, and 4BB
Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Avacta Group (AVCT), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.
Faron Pharmaceuticals Oy vs.
Ergomed (LON:ERGO) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.
In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 0.67 beat Ergomed's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.
71.1% of Ergomed shares are held by institutional investors. Comparatively, 10.7% of Faron Pharmaceuticals Oy shares are held by institutional investors. 18.2% of Ergomed shares are held by insiders. Comparatively, 31.8% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Faron Pharmaceuticals Oy received 75 more outperform votes than Ergomed when rated by MarketBeat users. Likewise, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 75.63% of users gave Ergomed an outperform vote.
Ergomed has a net margin of 9.87% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Ergomed's return on equity of 18.08% beat Faron Pharmaceuticals Oy's return on equity.
Ergomed has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.
Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.
Summary
Ergomed beats Faron Pharmaceuticals Oy on 9 of the 13 factors compared between the two stocks.
Get Faron Pharmaceuticals Oy News Delivered to You Automatically
Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Faron Pharmaceuticals Oy Competitors List
Related Companies and Tools
This page (LON:FARN) was last updated on 2/22/2025 by MarketBeat.com Staff
